Infinity Pharmaceuticals

Julian Adams joins Vedantra Pharmaceuticals as executive chairman

Thursday, January 12, 2017

Vedantra Pharmaceuticals, an immunotherapy company focused on developing products for cancer and infectious disease, has announced the appointment of Julian Adams, Ph.D., as executive chairman. Dr. Adams, who recently stepped down as president of Research and Development at Infinity Pharmaceuticals, will oversee strategic and operational responsibilities, fund raising and drive R&D program development for the company.

[Read More]

TrialNetworks wins Disruptive Technology and Innovator of the Year Award

Friday, April 11, 2014

TrialNetworks and its Clinical Trial Optimization System won the Disruptive Innovator and Technology of the Year award from Partnerships in Clinical Trials 2014. The award honors an individual or a company with a new disruptive technology platform that has increased the efficiency and quality of clinical trials. TrialNetworks technology is used by companies including Merck, Biogen Idec, Ariad Pharmaceuticals and Infinity Pharmaceuticals to optimize clinical operations from startup through closeout.

[Read More]

Infinity appoints Baselga, Berkowitz to board of directors

Thursday, March 13, 2014

Infinity Pharmaceuticals has appointed José Baselga M.D., Ph.D., and Jeff Berkowitz as independent members of its board of directors. Baselga, physician-in-chief at Memorial Sloan-Kettering Cancer Center, is an accomplished clinician and a thought leader in the PI3K field. Berkowitz, as the president of Walgreens Boots Alliance Development in Europe, has experience in pharmaceuticals, pharmacy, distribution and market access, pricing and reimbursement.

[Read More]

Infinity, Mundipharma extend global alliance

Tuesday, November 29, 2011

Infinity Pharmaceuticals has reported that Mundipharma International has committed to providing over $50 million in funding in 2013 for the continued development of IPI-145, Infinity’s potent, oral inhibitor of phosphoinositide-3-kinase (PI3K) delta and gamma, as well as development candidates arising out of Infinity’s innovative discovery programs. An extension of the companies’ global strategic alliance, this funding reflects the broad commercial potential of IPI-145 in both hematologic cancers and inflammatory conditions as well as the continued productivity of Infinity’s discovery and development programs.

[Read More]